Want to see HAE full AI Analyst Report?
Top Page
Haemonetics
(NYSE:HAE)
Select Model
Select Model
Rating:72Outperform
Price Target:
$116.00
▲(47.25% Upside)
Action:Reiterated
Date:08/19/26
HAE scores well on strong technical momentum and solid, improving cash flow generation, supported by upbeat earnings-call guidance and deleveraging. The main constraints are premium valuation (high P/E with no dividend yield provided) and tempered financial quality from higher leverage and recent margin pressure.
Positive Factors
Recurring Consumables Model
Haemonetics benefits from an installed-base model in which adopted collection and hospital systems drive repeat consumables, service and software revenue. This creates customer stickiness, improves revenue visibility and supports durable cash generation.
Negative Factors
Elevated Leverage
Higher leverage reduces financial flexibility compared with prior years and increases sensitivity to weaker earnings, interest costs or slower customer demand. Deleveraging is underway, but debt remains a meaningful constraint on resilience and capital allocation.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring Consumables Model
Haemonetics benefits from an installed-base model in which adopted collection and hospital systems drive repeat consumables, service and software revenue. This creates customer stickiness, improves revenue visibility and supports durable cash generation.
Read all positive factors
Haemonetics Key Performance Indicators (KPIs)
Any
Operating Income by Segment
Shows profit generated by each business unit, highlighting which segments contribute the most to the company’s bottom line and which consume investment. Helps investors see whether Haemonetics’ core operations are profitable, where margin improvement is possible, and how strategic choices or cost pressures affect overall earnings.
Shows profit generated by each business unit, highlighting which segments contribute the most to the company’s bottom line and which consume investment. Helps investors see whether Haemonetics’ core operations are profitable, where margin improvement is possible, and how strategic choices or cost pressures affect overall earnings.
Data provided by:
The Fly
The FlyHaemonetics (HAE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.93B
Dividend YieldN/A
Average Volume (3M)720.82K
Price to Earnings (P/E)52.5
Beta (1Y)0.52
Revenue Growth0.44%
EPS Growth-37.48%
CountryUS
Employees3,009
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)2.06
Shares Outstanding45,497,050
10 Day Avg. Volume569,544
30 Day Avg. Volume720,821
Financial Highlights & Ratios
PEG Ratio-0.69
Price to Book (P/B)3.20
Price to Sales (P/S)1.91
P/FCF Ratio9.79
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$102.38Price Target Upside29.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)5.29
Revenue Forecast (FY)$1.41B
Haemonetics Business Overview & Revenue Model
Company Description
Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops auto...
How the Company Makes Money
Haemonetics primarily makes money by selling medical devices and the recurring consumables and services tied to those devices. A large portion of revenue is generated from plasma and blood collection: the company places or sells apheresis collecti...
Haemonetics Earnings Call Summary
Earnings Call Date:Aug 06, 2026
(Q1-2027)
| % Change Since: |
Next Earnings Date:Nov 05, 2026
Earnings Call Sentiment Positive
The call communicated broad‑based operational momentum: solid revenue and EPS growth, strong performance across core platforms (notably Plasma/Persona PLUS, Hemostasis, and Vascular Closure), upgraded fiscal guidance, and exceptional cash generation and debt paydown activity. Offsetting items include near‑term margin compression from prior‑year software recognition and sequential MedSurg revenue timing, higher operating costs, some OEM/ensoETM weakness in IVT, and continued external inflation/FX/headwind risks. Management emphasized disciplined, conservative guidance and prioritized deleveraging while keeping optionality for share repurchases and organic investment.Positive Updates
Revenue Growth and Scale
Total first quarter revenue of $339 million, up 6% year-over-year on both reported and organic bases.
Negative Updates
Margin Pressures and Sequential Decline
Reported gross margin declined 40 basis points year-over-year to 60.4% and adjusted operating margin declined 70 basis points y/y to 23.4%; sequential adjusted margin declined ~100 basis points driven primarily by lower MedSurg revenue following a strong Q4 and external cost pressures.
Read all updates
Q1-2027 Updates
Positive
Negative
Revenue Growth and Scale
Total first quarter revenue of $339 million, up 6% year-over-year on both reported and organic bases.
Read all positive updates
Company Guidance
Haemonetics raised fiscal 2027 revenue guidance to 5–8% reported (4–7% organic), increased Apheresis guidance to low‑ to mid‑single‑digit growth and expects mid‑single‑digit MedSurg growth; Q1 revenue was $339M (+6% reported/organic) with adjusted EPS $1.14 (+4%), gross margin 60.4% (down 40 bps, but expanded ex‑software benefit), and adjusted operating margin 23.4% (down 70 bps YoY, -100 bps sequential) with a target of 50–100 bps of adjusted operating‑margin expansion for the year; cash flow remained strong with Q1 operating cash flow $52M (~3x PY), free cash flow up ~15x and Q1 FCF conversion 75% (106% trailing 12‑months), and the company reaffirmed FY'27 FCF conversion of ~80% of adjusted net income; balance sheet actions include $223M cash, net leverage ~2.69x EBITDA and $100M revolver repayment post‑quarter (leaving $200M outstanding), while management expects a ~$7M tariff refund in Q2 but anticipates offsetting external cost pressures.Haemonetics Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
58
Neutral
Cash Flow
78
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.35B | 1.33B | 1.36B | 1.31B | 1.17B | 993.20M |
| Gross Profit | 775.84M | 743.59M | 778.55M | 711.91M | 622.87M | 530.77M |
| EBITDA | 261.21M | 312.45M | 355.99M | 295.45M | 252.01M | 191.72M |
| Net Income | 96.29M | 97.31M | 167.68M | 117.56M | 115.40M | 43.38M |
Balance Sheet | ||||||
| Total Assets | 2.37B | 2.40B | 2.45B | 2.20B | 1.93B | 1.86B |
| Cash, Cash Equivalents and Short-Term Investments | 223.38M | 245.44M | 306.76M | 178.80M | 284.47M | 259.50M |
| Total Debt | 1.17B | 1.22B | 1.22B | 807.79M | 765.89M | 780.78M |
| Total Liabilities | 1.53B | 1.60B | 1.63B | 1.24B | 1.12B | 1.11B |
| Stockholders Equity | 837.10M | 796.32M | 820.84M | 959.96M | 818.00M | 749.42M |
Cash Flow | ||||||
| Free Cash Flow | 291.22M | 260.44M | 142.45M | 143.63M | 162.87M | 75.75M |
| Operating Cash Flow | 328.15M | 293.22M | 181.72M | 181.75M | 273.06M | 172.26M |
| Investing Cash Flow | -168.78M | -179.55M | -161.90M | -322.39M | -143.79M | -86.34M |
| Financing Cash Flow | -227.55M | -178.46M | 108.82M | 38.16M | -100.36M | -15.75M |
Haemonetics Technical Analysis
Positive
78.78
Price Trends
81.25
Positive
70.98
Positive
70.54
Positive
Market Momentum
6.61
Negative
84.33
Negative
95.38
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HAE, the sentiment is Positive. The current price of 78.78 is below the 20-day moving average (MA) of 89.18, below the 50-day MA of 81.25, and above the 200-day MA of 70.54, indicating a bullish trend. The MACD of 6.61 indicates Negative momentum. The RSI at 84.33 is Negative, neither overbought nor oversold. The STOCH value of 95.38 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HAE.
Haemonetics Risk Analysis
Haemonetics disclosed 76 risk factors in its most recent earnings report. Haemonetics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Haemonetics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | $1.92B | 28.39 | 16.42% | 0.94% | 11.85% | 38.09% | |
72 Outperform | $4.93B | 52.53 | 11.35% | ― | 0.44% | -37.48% | |
71 Outperform | $5.49B | 36.84 | 9.07% | ― | 10.51% | 20.67% | |
59 Neutral | $5.76B | -5.80 | -31.83% | 1.03% | -14.49% | -644.98% | |
57 Neutral | $4.68B | 152.11 | 1.41% | ― | -8.84% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
38 Underperform | $946.34M | -0.96 | -55.30% | ― | -2.57% | -135.75% |
* Healthcare Sector Average
HAE
Haemonetics
108.22
54.24
100.48%
ICUI
ICU Medical
182.53
60.78
49.92%
LMAT
Lemaitre Vascular
82.32
-13.16
-13.79%
MMSI
Merit Medical Systems
90.27
3.64
4.20%
QDEL
QuidelOrtho
14.85
-10.81
-42.13%
TFX
Teleflex
134.96
11.72
9.51%
Haemonetics Corporate Events
Business Operations and StrategyFinancial Disclosures
Haemonetics Signs Supply Agreement Expanding Plasma Collection Presence
Positive
Aug 18, 2026
On August 14, 2026, Haemonetics Corporation entered into a non‑exclusive supply agreement with CSL Plasma Inc. allowing CSL to use Haemonetics’ NexSys PCS devices with Persona PLUS technology and purchase associated disposables in the ...
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and ComplianceShareholder Meetings
Haemonetics Adds Veteran Director as Shareholders Back Governance
Positive
Jul 28, 2026
On July 24, 2026, Haemonetics’ board elected veteran diagnostics and life sciences executive Martin Madaus as a director, with plans for him to join the Audit and Governance and Compliance committees and receive standard non-employee directo...
Business Operations and StrategyFinancial Disclosures
Haemonetics Unveils New Two-Segment Financial Reporting Structure
Positive
Jun 5, 2026
On June 5, 2026, Haemonetics announced it will overhaul its financial reporting structure, consolidating its Plasma and Blood Center units into a single Apheresis segment and renaming its Hospital unit as MedSurg to better reflect its technologies...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.